LLY
Eli Lilly and Company
LLY has the edge over SIBN overall, supported by stronger fundamentals and stronger modeled upside.
SIBN
SI-BONE, Inc.
SIBN's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SIBN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
SIBN's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SIBN PE Valuation
SIBN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SIBN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect SIBN's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SIBN on earnings quality, reporting a profit while its opponent remains loss making.
SIBN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.31 | +$0.19 |
| Q2 2026 | -$0.34 | +$0.21 |
| Q1 2026 | -$0.39 | +$0.24 |
| Q4 2025 | -$0.44 | +$0.31 |
| Q3 2025 | -$0.50 | +$0.41 |
| Q2 2025 | -$0.55 | +$0.45 |
| Q1 2025 | -$0.63 | +$0.45 |
| Q4 2024 | -$0.75 | +$0.38 |
SIBN is still losing money, but far less than before: $0.31 per share over the past year, against $1.98 at its worst in mid-2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SIBN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SIBN on profitability, with a higher operating margin.
SIBN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.7M | +14% |
| Q2 2026 | $56M | +15% |
| Q1 2026 | $52.6M | +11% |
| Q4 2025 | $56.3M | +15% |
| Q3 2025 | $48.7M | +21% |
| Q2 2025 | $48.6M | +22% |
| Q1 2025 | $47.3M | +25% |
| Q4 2024 | $49M | +26% |
SIBN's revenue has grown year over year every quarter since late 2020: $56M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.8% | +3.3 points |
| Q2 2026 | -8.6% | +5.8 points |
| Q1 2026 | -9.7% | +6.1 points |
| Q4 2025 | -4.4% | +6.8 points |
| Q3 2025 | -11% | +7.9 points |
| Q2 2025 | -14% | +11 points |
| Q1 2025 | -16% | +16 points |
| Q4 2024 | -11% | +21 points |
SIBN's operating margin was −7.8% last quarter, up 3.3 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SIBN on cash generation, producing positive trailing cash flow while its opponent burns cash.
SIBN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$427K | +$193K |
| Q2 2026 | -$768K | +$1.2M |
| Q1 2026 | -$3.4M | +$3.5M |
| Q4 2025 | $440K | +$1.5M |
| Q3 2025 | -$620K | +$2.1M |
| Q2 2025 | -$1.9M | +$7.5M |
| Q1 2025 | -$7M | +$2.7M |
| Q4 2024 | -$1.1M | +$2.3M |
SIBN has burned cash in almost every quarter: −$4M over the past year, against −$11M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SIBN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SIBN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +422K shares |
| 1 year | +4% | +1.7M shares |
| 3 years | +12% | +4.6M shares |
| 5 years | +35% | +11.6M shares |
| Available history | +82% | +20.2M shares |
SIBN has 45M diluted shares, up 4% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SIBN Net Leverage
SIBN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SIBN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.9 | Overbought |
| Stochastic | 76.7 | Neutral |
SIBN's weekly RSI is 75 (overbought) and its Stochastic is 77 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SIBN PE vs Healthcare Sector
SIBN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
SIBN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.9 | 16% above |
| 20 week MA | $19.3 | 25% above |
| 50 week MA | $17.1 | 41% above |
| 100 week MA | $16.6 | 45% above |
| 200 week MA | $17.5 | 38% above |
SIBN has climbed back above all five of its weekly moving averages, and it's now 38% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SIBN on returns for 2026, with the stronger performance.
SIBN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.1 | $30.3 | +43% |
| 2021 | $30.3 | $21.9 | -28% |
| 2022 | $21.9 | $11.8 | -46% |
| 2023 | $11.8 | $21.0 | +78% |
| 2024 | $21.0 | $13.7 | -35% |
| 2025 | $13.7 | $20.4 | +48% |
| 2026 YTD | $20.4 | $24.1 | +19% |
SIBN has finished lower in three of the last six years. It's up 19% so far in 2026.